Fig. 1
From: Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Timeline of approved ICIs. IPI, ipilimumab; NIVO, nivolumab; PEMBRO, pembrolizumab; ATEZO, atezolizumab; AVE, avelumab; DURVA, durvalumab; CEMI, cemiplimab. mNCSLC, metastatic non-small cell lung cancer; wt, wild type; RCC, renal cell carcinoma; cHL, classical Hodgkin lymphoma; UC, urothelial cancer; HNSCC, head and neck squamous cell carcinoma; MCC, Merkel cell carcinoma; mCRC, metastatic colorectal cancer; HCC, hepatocarcinoma; GEJ, gastroesophageal junction; PMBCL, primary mediastinal B-cell lymphoma; SCLC, small cell lung cancer; SCC, squamous cell carcinoma; TNBC, triple negative breast cancer; NMIBC, non-muscle-invasive bladder cancer; ESCC, esophageal squamous cell carcinoma; BCC, basal cell carcinoma